Company Filing History:
Years Active: 2018
Title: The Innovations of Daniel Rothenstein
Introduction
Daniel Rothenstein is an accomplished inventor based in Ramat Hasharon, Israel. He has made significant contributions to the field of medical science, particularly in the prevention of ischemia reperfusion injury (IRI) in organs. His innovative work has the potential to improve outcomes for patients undergoing organ transplantation.
Latest Patents
Rothenstein holds a patent for "Methods and compositions for preventing ischemia reperfusion injury in organs." This invention focuses on compounds and methods aimed at preventing IRI, especially in organs aged 35 years and older. The patent outlines specific uses, including the prevention of IRI in native organs in vivo, reimplantations, and transplantations of donor organs. Additionally, it addresses the prophylaxis of delayed graft function (DGF) and aims to reduce the frequency, amount, and duration of dialysis in recipients of deceased donor kidney transplantations. The methods involve contacting the organ in vivo or ex vivo with a temporary p53 inhibitor, and novel temporary dsNA p53 inhibitors are also provided.
Career Highlights
Rothenstein is currently associated with Quark Pharmaceuticals, Inc., where he continues to advance his research and innovations. His work is pivotal in the development of therapies that can significantly enhance the success rates of organ transplants.
Collaborations
He collaborates with notable colleagues, including Elizabeth C. Squiers and Shai Erlich, who contribute to the research and development efforts at Quark Pharmaceuticals.
Conclusion
Daniel Rothenstein's innovative contributions to the field of organ transplantation highlight the importance of research in preventing ischemia reperfusion injury. His work not only advances medical science but also has the potential to save lives through improved transplant outcomes.